Phase 2 Psoriasis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are currently experiencing a moderate-to-severe flare of Generalized Pustular Psoriasis (GPP), meaning their condition scores 3 or higher on a standard doctor-rated scale, new or worsening pustules are present with a pustule-specific score of 2 or higher, and at least 5% of their body surface is covered with pustules
• Men and women of reproductive age who have no plans to have children, and who are willing to use reliable contraception throughout the study and for 6 months after the last dose of the study drug
• People who fully understand and voluntarily sign a consent form, and who are willing and able to attend all scheduled study visits

Who may not be able to join:

• People whose pustular skin condition was triggered by a drug reaction (a condition called AGEP)
• People who have a condition known as SAPHO syndrome (a disorder involving joints, skin, and bones)
• People who have another active inflammatory or autoimmune disease — such as rheumatoid arthritis, psoriatic arthritis, lupus, inflammatory bowel disease, or uveitis — that requires treatment with immune-suppressing medications
• People who the study doctor believes are at higher risk of serious infections, such as those with a recent severe infection, a weakened immune system, HIV, or a history of organ or stem cell transplant
• People who have received a live vaccine within 6 weeks before the first study dose, or who plan to receive a live vaccine during the study or within 6 weeks after the final dose
• People who have had a serious injury or major surgery within 1 month before the first study dose, or who plan to have elective surgery during the study period
• People who currently have, are suspected of having, or have had cancer within the past 5 years
• People with a history of severe allergic reactions (grade 3–4) to other monoclonal antibody treatments, or who are known to be allergic to protein-based drugs, recombinant proteins, or any ingredient in the study drug (HB0034)
• People who are pregnant, breastfeeding, or have a positive pregnancy test — though women who stop breastfeeding before the first dose and remain breastfeeding-free until 16 weeks after the trial ends would not be excluded on this basis (confirm with trial site)
• People who are currently in another clinical trial, or who have participated in a clinical trial of any drug or device within the past 30 days — or within 5 half-lives of that drug, whichever is the longer period
• People who are unlikely to follow the study requirements, such as attending follow-up visits reliably and completing the full study
• People whom the study doctor considers unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.